ALNY Stock Recent News

Friday, Alnylam Pharmaceuticals Inc. ALNY stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM). Topline data was revealed in June.

Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.

Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.

Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Christine Lindenboom - SVP, IR and Corporate Communications Yvonne Greenstreet - CEO Tolga Tanguler - CCO Pushkal Garg - CMO Jeff Poulton - CFO Conference Call Participants Tazeen Ahmad - Bank of America Maury Raycroft - Jefferies Julian Pino - Stifel Kostas Biliouris - BMO Capital Markets Jessica Fye - JPMorgan David Lebowitz - Citi Gena Wang - Barclays Ritu Baral - TD Cowen Mike Ulz - Morgan Stanley William Pickering - Bernstein Myles Minter - William Blair Luca Issi - RBC Capital Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Second Quarter 2024 Conference Call.

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $0.74 per share. This compares to loss of $2.21 per share a year ago.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ: ALNY ) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has several drugs already on the market, the biopharma is not yet profitable.